HRTX Q4 2025 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$162M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41M-0.5% YoY

Gross Profit

$33M81.2% margin

Operating Income

$38,0000.1% margin

Net Income

-$3M-7.3% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+6.2%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$256M

Total Liabilities

$242M

Stockholders' Equity

$14M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$41M	-0.5%
Gross Profit	$33M	$31M	+7.8%
Operating Income	$38,000	$4M	-99.1%
Net Income	-$3M	$4M	-180.6%

Revenue Segments

C I N V A N T I

$23M62%

Z Y N R E L E F

$13M34%

S U S T O L

$1M4%